Trillium Therapeutics Statistics
Share Statistics
Trillium Therapeutics has 0
shares outstanding. The number of shares has increased by null%
in one year.
| Shares Outstanding | n/a |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | n/a |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | n/a |
| FTD / Avg. Volume | n/a |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -20.76 and the forward
PE ratio is null.
Trillium Therapeutics's PEG ratio is
0.36.
| PE Ratio | -20.76 |
| Forward PE | n/a |
| PS Ratio | 8324.29 |
| Forward PS | n/a |
| PB Ratio | 4.42 |
| P/FCF Ratio | -54.19 |
| PEG Ratio | 0.36 |
Financial Ratio HistoryEnterprise Valuation
Trillium Therapeutics has an Enterprise Value (EV) of 985.23M.
| EV / Sales | 6656.93 |
| EV / EBITDA | -16.8 |
| EV / EBIT | -43.34 |
| EV / FCF | -43.34 |
Financial Position
The company has a current ratio of 13.94,
with a Debt / Equity ratio of 0.
| Current Ratio | 13.94 |
| Quick Ratio | 13.94 |
| Debt / Equity | 0 |
| Debt / EBITDA | -0.01 |
| Debt / FCF | -0.04 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is -21.28% and Return on Invested Capital is -22.06%.
| Return on Equity | -21.28% |
| Return on Assets | -19.73% |
| Return on Invested Capital | -22.06% |
| Revenue Per Employee | $4,484.85 |
| Profits Per Employee | $-1,798,363.64 |
| Employee Count | 33 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 102K |
| Effective Tax Rate | -0.17% |
Stock Price Statistics
The stock price has increased by 0% in the
last 52 weeks. The beta is 1.9, so Trillium Therapeutics's
price volatility has been higher than the market average.
| Beta | 1.9 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | n/a |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | n/a |
| Average Volume (20 Days) | 1,982,854 |
Income Statement
In the last 12 months, Trillium Therapeutics had revenue of 148K
and earned -59.35M
in profits. Earnings per share was -0.71.
| Revenue | 148K |
| Gross Profit | 148 |
| Operating Income | -61.45M |
| Net Income | -59.35M |
| EBITDA | -58.65M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -0.71 |
Full Income StatementBalance Sheet
The company has 247.6M in cash and 831K in
debt, giving a net cash position of 246.77M.
| Cash & Cash Equivalents | 247.6M |
| Total Debt | 831K |
| Net Cash | 246.77M |
| Retained Earnings | -249.38M |
| Total Assets | n/a |
| Working Capital | n/a |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -22.73M
and capital expenditures 0, giving a free cash flow of -22.73M.
| Operating Cash Flow | -22.73M |
| Capital Expenditures | n/a |
| Free Cash Flow | -22.73M |
| FCF Per Share | -0.27 |
Full Cash Flow StatementMargins
Gross margin is 0.1%, with operating and profit margins of -41523.65% and -40098.65%.
| Gross Margin | 0.1% |
| Operating Margin | -41523.65% |
| Pretax Margin | -40029.73% |
| Profit Margin | -40098.65% |
| EBITDA Margin | -39630.41% |
| EBIT Margin | -41523.65% |
| FCF Margin | -15360.14% |
